HDGF and neoplasm: In established TM00219 tumors (257–427 mm3), the humanized anti-HDGF antibody H3 was given at 13 mg/kg concurrently with the start of osimertinib dosing and subsequently maintained at twice per week till tumor relapse or up to 200 days.